Five-year follow-up of a randomized weight loss trial on a digital health behaviour change support system

Five-year follow-up of a randomized weight loss trial on a digital health behaviour change support system

Introduction

The challenge in treating overweight and obesity is to sustain reduced weight. Obesity should be approached as a chronic condition requiring longer-term support and treatment [1]. Lifestyle interventions are effective in achieving weight loss in the short term, but preserving the results is often challenging [2,3,4]. Better weight management methods are needed to ensure long-term weight maintenance. Currently, there is no universally effective approach to weight maintenance [4].

Digital technologies have significant potential for engaging people with health behaviour change and helping weight reduction [1, 5]. Mobile application is an easily accessible and potential platform for obesity treatment as most adults own a smartphone and half have downloaded a health-related mobile app [5, 6]. There is evidence that web-based interventions may be useful in weight loss and maintenance in the short term [1, 3]. A meta-analysis showed that digital interventions may be more effective in weight loss than a non-digital intervention in the short-term [7]. Some studies have shown that interactive technology interventions help reduce weight and maintain weight loss for up to two years [3, 8]. Currently, personal contact intervention, including telephone and face-to-face contact, seems to be the most effective both in weight loss and maintenance [3, 9].

We previously performed a randomized clinical trial on the effectiveness of a web-based health behaviour change support system (HBCSS) that utilizes persuasive systems design (PSD) and methods of cognitive behavioural therapy (CBT). We had six intervention groups: CBT-based group counselling, self-help guidance-based group counselling (SHG), and usual care further divided into the HBCSS and non-HBCSS groups [8]. The trial demonstrated that one-year treatment with HBCSS was effective for weight loss, and remarkably, the weight loss result was maintained for one year after the intervention, even when HBCSS was utilized without any face-to-face counselling [8]. Weight reduction in CBT-based counselling with HBCSS was 4.1% at 12 months and 3.4% at 24 months. HBCSS alone achieved a 1.6% weight reduction at 24 months.

Here we report the five-year outcome of the HBCSS and/or group counselling treatment. Our primary aim was to assess the long-term effectiveness of HBCSS in weight control.

Materials and methods

Participants and randomization

An invitation letter was sent to 11,400 people aged 20–60 living in Oulu, Finland, and 1065 volunteers were assessed for eligibility. The inclusion criteria were BMI (27–35 kg m−2), access to the internet, no health-related restrictions to losing weight, and no other treatment for obesity. After exclusions due to significant illness or abnormal laboratory values, 532 participants were randomized into six groups in two phases (Fig. 1). First, participants were divided into three groups, one control group and two groups with different face-to-face group counselling methods. Secondly, these three groups were divided into web-based HBCSS users and non-users.

Fig. 1: Participant flow during the 5-year follow-up.
Five-year follow-up of a randomized weight loss trial on a digital health behaviour change support system

The flowchart represents all groups, either with or without HBCSS. The completers are the participants measured at baseline and the 5-year visit. Detailed changes in participants, including the 1- and 2-year visits, are presented in a previous publication [8].

Full size image

At baseline, 532 participants were randomly assigned to the study arms. Between the baseline and five-year visits, 129 participants (24.2%) dropped out. The completers are the participants measured at baseline and the 5-year visit. All randomized participants (except for one) were approached and invited to the five-year visit, even if they had not visited the research centre after the baseline visit.

Intervention and treatment arms

CBT group counselling included eight sessions with qualified or student clinical nutritionists who had knowledge of CBT. Treatment aims were to (1) lose and maintain 5% weight loss, (2) improve eating behaviour, and (3) decrease health risks related to overweight and obesity (e.g., diabetes, cardiovascular diseases). Group counselling with SHG included two sessions with a registered nurse. The sessions were based on Elvira counselling model, which utilizes constructive learning theory and stages of change model [10, 11]. The sessions aimed to help with lifestyle changes and eating behaviour. The control group received usual care usually given in primary health care, including information about health and weight management and metabolic syndrome (a leaflet and personal laboratory results).

The web-based HBCSS was a 52-week programme based on PSD combined with CBT methods. The programme guided the participants towards a better lifestyle, weight loss, and a healthier state. The system included motivative functions, e.g., the possibility to set goals and follow progress. It also provided information about health and healthy lifestyle-related topics. Software features implemented in the system supported users to carry out their primary task, computer-human dialogue, perceived credibility, and social influence. These included specifically design principles of self-monitoring, reduction, tunnelling, tailoring, praise, reminders, suggestion, liking, verifiability, social learning, and social facilitation [12, 13]. Detailed information about HBCSS, treatment arms and sample size calculations are presented in the previous publication [8].

Measurements

Participants in each group were followed up at baseline and one year, two years, and five years after the baseline visit in the research centre at the Oulu University Hospital. Waist circumference, weight, and blood pressure were measured at each visit. Height was measured at baseline and five years. Information about the medications of the participants was collected at each visit.

Statistical methods

The primary outcome was the weight loss (kg) from the baseline to five years. Changes in weight from baseline to five years were compared in six groups among all participants based on the intention-to-treat principle.

A linear mixed-effect model (LMM) (as primary analysis), where (six) group and time were fixed effect factors was used to examine the differences in weight from baseline to 5 years adjusting for age and sex [14]. Group and time interaction was included in the model to examine whether mean change over time was different between groups. Data included some missing values, but they were assumed to be at random. The same model was used with imputed values (both the Last Observation Carried Forward (LOCF) and Return-To-Baseline (RTB)) where data were missing and for completers as sensitivity analyses. Primary analysis and sensitivity analyses were based on intention-to-treat principles. Primary analysis was also used to examine the differences between HBCSS groups and non-HBCSS groups.

Furthermore, the supplementary net incremental Area-Under-the-curve (AUC) analysis was used to compare weight changes during the five years of follow-up in HBCSS and non-HBCSS groups. The AUC analysis visualises and outlines the weight change trend over the five-year period and was therefore performed as an off-protocol analysis. The calculations of incremental AUCs subtracted the baseline weight from the weight at one-year, two-year, and five-year time points. If the subtraction of the baseline from the subsequent time point resulted in a negative value, leading to a negative peak in incremental AUC calculation, the resulting negative peak area was subtracted from the positive peak area (net area calculation). The inclusion criteria for AUC analysis were that the baseline and at least one other time point measurement were available. The five-year measure got a value of 0 (no change in weight) if missing. The net areas from AUC analysis were run by analysis of variance (ANOVA). Intragroup changes were analysed with One-Sample T Test. IBM SPSS Statics version 26.0 (IBM Corp., Armonk, NY, USA) was used for the analyses. GraphPad Prism 9 (GraphPad Software Inc., San Diego, CA, USA) was utilized for the AUC analyses.

In addition, differences in the weight change proportions between study arms were calculated with Chi-square analysis. The changes in the number of lipid, cardiovascular and diabetes medications between HBCSS and non-HBCSS groups were analysed with the Chi-Square Test. p-values less than 0.05 were considered statistically significant.

Results

Baseline characteristics

The mean age (with standard deviation) of study subjects (n = 532) was 45.9 ( ± 9.9) years, mean body weight was 89.5 (±11.2) kg, and mean BMI was 30.4 ( ± 2.1) kg m−2. Of all participants, 50.8% (n = 270) were men, and 49.2% (n = 262) women. At baseline, 52.3% of the participants were living with obesity (BMI > 30 kg m−2) and 47.7% were living with overweight (BMI 27–30 kg m−2). Detailed information about baseline characteristics is presented in the previous publication [8].

Primary outcome

Among all participants (n = 532) included in the analysis, there was no significant difference between the six groups at five years (p > 0.05) in weight change (Fig. 2, Supplementary Table 1). The SHG group without HBCSS had a statistically significant increase in weight (%) from baseline (3.1, 95% CI 0.6–5.6, p = 0.010). The other groups did not have a significant increase in weight. There was no statistically significant difference between HBCSS group and non-HBCSS group. Mean weight change (%) (95% CI) from baseline among HBCSS and non-HBCSS users was 1.5 (−0.02 to 2.9), p = 0.056 and 1.9 (0.3 to 3.3), p = 0.005, respectively, at five years. Results of sensitivity analyses were similar. Those results are not shown.

Fig. 2: Effect of digital lifestyle counselling on weight—5-year outcomes of a randomized clinical trial.
figure 2

Linear mixed-effect model was used to examine the differences in weight change (kg). Data is presented in means (%) with 95% confidence intervals. Grey line, No HBCSS; black line, HBCSS. HBCSS, health behaviour change support system. *p < 0.05.

Full size image

Individual changes in weight between baseline and five years (Fig. 3) shows the heterogeneity in the success of the weight change during the follow-up.

Fig. 3: Weight change (%) between baseline and five years among each participant (completers).
figure 3

Panels (A, B) represent CBT groups, (C, D) SHG groups and (E, F) control groups. HBCSS health behaviour change support system, CBT cognitive behavioural therapy-based group counselling, SHG self-help guidance.

Full size image

Net area in weight (Supplementary Table 2) in the AUC analysis was statistically significantly more negative in groups using the HBCSS compared with groups without HBCSS (Supplementary Fig. 1). The mean weight net area was –3.47 (p = 0.018) in the combined HBCSS groups and 1.34 (p = 0.340) in non-HBCSS groups, with significant difference between groups (p = 0.018) (Supplementary Table 2). CBT + HBCSS group had the most negative net area –9.06 (p < 0.001 within group and p = 0.035 between the three HBCSS groups). There were no significant differences between the groups without HBCSS.

Proportions of weight change

Dividing the participants into three groups by success in weight loss (weight gain, weight loss 0–4.99% and weight loss ≥5%) demonstrates the proportions of weight change. A weight reduction of 5% or more is considered clinically significant. At five years, the succeeders lost weight regardless of using HBCSS (Fig. 4). Among completers, the clinically significant weight reduction of ≥5% was recorded in the range of 10.8–25.4% of participants in groups using HBCSS and in the range of 8.2–19.1% of participants in groups without HBCSS. There were no differences between groups in proportions of weight change (p > 0.05).

Fig. 4: Success of weight loss at five years among completers.
figure 4

Green bar represents weight loss ≥5%, yellow bar 0–4.99% and red bar weight gain. HBCSS health behaviour change support system, CBT cognitive behavioural therapy-based group counselling, SHG self-help guidance, CTRL control.

Full size image

Effects on medications

Fewer blood pressure medications were started over the five-year period in the HBCSS group compared with non-HBCSS group (21 vs. 34, p = 0.046). The same trend was observed in diabetes medications, but the difference was not statistically significant (8 vs. 13, p = 0.230). There were no statistically significant differences in lipid medications started (p = 0.669).

Discussion

We have previously shown that a 52-week-long web-based HBCSS intervention effectively reduces weight for up to two years [8]. Our current extended follow-up study demonstrates that the non-HBCSS group showed significant weight gain from baseline at five years. This is in accordance with previous observational studies showing an average weight gain of about 400 g per year [15]. Among HBCSS users the weight gain was less extensive although there was no statistical difference between the combined HBCSS group and the combined non-HBCSS group.

The net area under the curve analysis (AUC) showed differences in weight favouring the HBCSS intervention groups during the totality of five-year follow-up, reflecting the previously demonstrated effectiveness of the HBCSS intervention for weight loss at two years. After five years, the best results among the three HBCSS groups in the AUC analysis were achieved in the CBT + HBCSS group. There is evidence that the benefits of weight loss associated with the risk of type 2 diabetes, cardiovascular diseases, and other obesity and overweight related conditions are remarkable at over 5% weight loss [16, 17]. Also, more moderate weight loss (from 2% to 5%) is associated with improved fasting glucose and HbA1c levels [17]. Thus, using the HBCSS intervention combined with CBT-based group counselling may lead to a better state of health because the weight remains lower for a longer time. In addition, our finding of the decrease in the need for antihypertension therapy may indicate that the significant weight loss by HBCSS in the early years, as indicated by AUC analyses, has a health-promoting legacy effect reflected on the better blood pressure control.

Previous studies have shown that weight maintenance is a significant problem in treating overweight and obesity [1]. Short-term lifestyle changes can be very successful [2,3,4]. The patterns of curves from two to five years among the HBCSS users indicate that additional support may be required for sustained lifestyle change results and to prevent regaining weight. To maintain the results in the long term, e.g., face-to-face, or web-based counselling could be needed if weight is regained. One of the potential options is to repeat the HBCSS intervention a few years after the first intervention period. It should be noted that the weight-regain process is also a result of physiological processes, for example, metabolic adaptation and hormonal changes, in addition to psychological and lifestyle-related factors [18].

Our study searched for an effective, low-cost method for treating overweight and obesity. From a public health perspective, web-based interventions in lifestyle change might be desirable because of the excellent opportunity to treat many individuals at a time at a low cost. Also, in the future, the focus must be on preventing overweight and obesity. Prevention of weight gain and maintaining a healthy weight are considered less challenging, less expensive, and potentially more effective than treatment of obesity [19].

The exceptionally long follow-up period, the original randomized trial design, the number of participants, and the anthropometric measurements performed by study personnel support the reliability, quality, and uniqueness of this study. Considering that only 129 (24.2%) participants dropped out between the baseline and five-year visit, the participants were well committed to the trial. The large number of completers increases the reliability of the results of this study. The practical experience and the previous scientific evidence of the difficulty of maintaining weight loss are also in line with our findings. This study did not include an analysis of the factors influencing the weight gain of the subjects, such as hormonal changes, psychological factors, and life situations.

Conclusions

Our extended follow-up study shows that the previously demonstrated 2-year weight benefits of the 12-month HBCSS intervention were not maintained at 5 years better than with the non-HBCSS control intervention. However, there were significant weight differences favouring HBCSS over the whole 5-year period, with HBCSS + CBT-based group counselling having the most beneficial effect on weight among the three HBCSS groups. The legacy effect on the need of blood pressure medications supports the benefits of the HBCSS when aiming to lower the risk of cardiovascular diseases. In the future, there is a particular need for an effective tool for maintaining weight loss.

Related Articles

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored. Compared with conventional treatments, small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing. As a result of recent technological advances, efficient small nucleic acid delivery for therapeutic and biomedical applications has been achieved, accelerating their clinical translation. Here, we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms. We also discuss the key advances in the design, development and therapeutic application of each delivery platform. Furthermore, this review presents comprehensive profiles of currently approved small nucleic acid drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers and 6 siRNA drugs, summarizing their modifications, disease-specific mechanisms of action and delivery strategies. Other candidates whose clinical trial status has been recorded and updated are also discussed. We also consider strategic issues such as important safety considerations, novel vectors and hurdles for translating academic breakthroughs to the clinic. Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously “undruggable” targets, suggesting that they could be useful for guiding the development of additional clinical candidates.

Attentional bias towards smartphone stimuli is associated with decreased interoceptive awareness and increased physiological reactivity

Excessive smartphone use has been linked to negative psychological outcomes and may also be associated with cognitive impairments and disruptions in mind-body interaction, though the underlying mechanisms remain unclear. Here, we investigated attentional bias towards marginal smartphone stimuli and its relationship with interoceptive awareness and physiological cue reactivity in healthy young adults. Fifty-eight participants completed a letter detection task with varying perceptual loads, during which task-irrelevant smartphone-related or scrambled images were presented in the background. Cardiac responses were recorded to assess physiological reactivity. Participants also completed two questionnaires for interoceptive awareness and self-report smartphone addiction. Using a designed and automated clustering based on behavioural responses, participants were classified into two groups: one group exhibited distraction from smartphone background only under low perceptual load, while the other showed consistent attentional bias regardless of load. Notably, the latter group reported significantly lower interoceptive awareness and higher smartphone addiction scores. Additionally, they exhibited heart rate acceleration in response to smartphone stimuli, indicating heightened arousal, whereas the former group showed heart rate deceleration. These findings demonstrate that consistent attentional bias towards smartphone stimuli is associated with reduced interoceptive awareness, specifically a decreased tendency to notice and trust internal bodily sensations, and increased physiological reactivity.

Responses

Your email address will not be published. Required fields are marked *